Mohamed Elbadry

Prof. Dr. Mohamed Elbadry

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2020 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
SSShemal M. Shah
Shemal M. Shah
HRHolly Rodin
Holly Rodin
HPHope Pogemiller
Hope Pogemiller
OMOluwadayo Magbagbeola
Oluwadayo Magbagbeola
KSKenneth Ssebambulidde
Kenneth Ssebambulidde
JDJose Debes
Jose Debes
Hepatitis B virus (HBV) vaccination patterns and the understanding of its risks among healthcare workers (HCWs) is a critical step to decrease transmission. However, the depth of this understanding is understudied. We distributed surveys to HCWs in 12 countries in Africa. Surveys had nine multiple-choice questions that assessed HCWs’ awareness and understanding of HBV. Participants included consultants, medical trainees, nurses, students, laboratory personnel, and other hospital workers. Surveys were completed anonymously. Fisher’s exact test was used for analysis, with a P-value of < 0.05 considered significant; 1,044 surveys were collected from Kenya, Egypt, Sudan, Tanzania, Ethiopia, Uganda, Malawi, Madagascar, Nigeria, Cameroon, Ghana, and Sierra Leone. Hepatitis B virus serostatus awareness, vaccination rate, and vaccination of HCWs’ children were 65%, 61%, and 48%, respectively. Medical trainees had higher serostatus awareness, vaccination rate, and vaccination of their children than HCWs in other occupations (79% versus 62%, P < 0.001; 74% versus 58%, P < 0.001; and 62% versus 45%, P = 0.006, respectively). Cost was cited as the most frequent reason for non-vaccination. West African countries were more aware of their serostatus but less often vaccinated than East African countries (79% versus 59%, P < 0.0001 and 52% versus 60%, P = 0.03, respectively). West African countries cited cost as the reason for non-vaccination more than East African countries (59% versus 40%, P = 0.0003). Our study shows low HBV serostatus awareness and vaccination rate among HCWs in Africa, and reveals gaps in the perception and understanding of HBV prevention that should be addressed to protect HCWs and improve their capacity to control HBV infection.

24 May 2018 in Expert Review of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
MEMohamed El-Kassas
Mohamed El-Kassas
MAMohamed Alboraie
Mohamed Alboraie
DODalia Omran
Dalia Omran
MSMohamed Salaheldin
Mohamed Salaheldin
MWMohamed Naguib Wifi
Mohamed Naguib Wifi
GEGamal Esmat
Gamal Esmat
Background: A large Egyptian treatment program for HCV was launched in2014 after the introduction of direct-acting antiviral agents (DAAs). This program depended mainly on establishing specialized independent centres for HCV treatment. These centres represent the major strengths in the Egyptian model of care, as they provide integrated care for HCV patients and have enabled Egypt to treat more than one million patients in 3 years. The New Cairo Viral Hepatitis Treatment Center (NCVHTC) is an example of these specialized centres. Methods: The Egyptian experience in the management of HCV was evaluated by analysing the data of real-life HCV management in the NCVHTC from 2014 to 2017. Results of different treatment regimens in addition to their strengths, limitations and areas for improvement are discussed in this report. Results: A total of 7042 HCV patients have been evaluated for treatment in the NCVHTC. Among them, 5517 patients received treatment by seven different DAA regimens with excellent results. Conclusions: All regimens were highly effective at treating HCV in a real-life setting, apart from SOF/RBV, which was the least effective. A nationwide screening program and enhancing the follow-up of treated patients are the main missing pillars in the Egyptian model.

1 June 2019 in Arab Journal of Gastroenterology
Verified
Journal Article
Closed access
MAMohamed Alboraie
Mohamed Alboraie
NYNaglaa Youssef
Naglaa Youssef
ASAhmed F Sherief
Ahmed F Sherief
SAShimaa Afify
Shimaa Afify
MWMohamed-Naguib Wifi
Mohamed-Naguib Wifi
MEMohamed El-Kassas
Mohamed El-Kassas

23 May 2025 in Liver International
Verified
Journal Article
Closed access
MEMohamed El-Kassas
Mohamed El-Kassas
MVMarcela Villota‐Rivas
Marcela Villota‐Rivas
KAKhalid A Alswat
Khalid A Alswat
KAKhalid Al-Naamani
Khalid Al-Naamani
Yusuf YilmazYusuf Yilmaz
Yusuf Yilmaz
TCthe Steatotic Liver Disease Study Foundation in Middle East and North Africa (SLMENA) Collaborators
the Steatotic Liver Disease Study Foundation in Middle East and North Africa (SLMENA) Collaborators

14 November 2021 in Afro-Egyptian Journal of Infectious and Endemic Diseases
Verified
Journal Article
Open access
PDF file
AMAbdelmajeed Moussa
Abdelmajeed Moussa
NENoha H Eltaweel
Noha H Eltaweel
MEMohamed Elbadry
Mohamed Elbadry
Background and study aim: Ulcerative colitis (UC) is a chronic remitting relapsing disease affecting the colon. We aimed to study the epidemiology and clinical characteristics of UC patients in Aswan ‎governorate - south of Upper Egypt ‎. Methods: ‎‎‎ Our study was a retrospective observational cross-sectional study including all patients who ‎attend the inflammatory bowel disease (IBD) clinic of tropical medicine and gastroenterology ‎department- Aswan university hospital over the five years period from 2015 to 2020 in whom ‎the diagnosis of UC was confirmed by clinical, laboratory, endoscopic and histological ‎examinations‎‎.‎ Results: A total of 26 patients with established diagnosis of UC were included in this study. Their mean± ‎‎(SD) age at diagnosis was 30± (8.7) years. In our study the male: female ratio was 1.6:1. Only 4 ‎‎(15.4%) patients had positive family history of UC. Bleeding per rectum was the main ‎presenting symptom in 76.9%, most of the studied patients had no associated extra intestinal ‎manifestations at presentations; while arthralgia, oral ulcers, sacroiliitis or arthralgia and ‎sacroiliitis were associated symptoms in 7.6%, 3.8%, 11.5% or 3.8% of patients respectively. There was no statistically significant difference upon comparing laboratory data between the ‎two age groups (more or less than 40 years) or between positive and negative extra intestinal ‎manifestations. However, the level of fecal calprotectin and serum level of C-reactive protein ‎‎(CRP), Erythrocyte sedimentation rate (ESR), platelets (PLT) and white blood cells (WBCs) count ‎were raised with the increase in the clinical or endoscopic severity indices, while serum ‎albumin and hemoglobin were dropped‎‎. Conclusion: Epidemiology and clinical characteristics of UC patients in Upper Egyptian population closely ‎resembled those of the Lower Egypt and Middle East. UC was more common in males and had ‎mild and distal pattern‎‎‎.

26 March 2021 in Egyptian Liver Journal
Verified
Journal Article
Open access
PDF file
SZSamy Zaky
Samy Zaky
MAMohamed Alboraie
Mohamed Alboraie
MEMohamed Elbadry
Mohamed Elbadry
MMMohamed A. Metwally
Mohamed A. Metwally
AAAhmed Abdelaziz
Ahmed Abdelaziz
GEGamal Esmat
Gamal Esmat
Chronic liver diseases are common worldwide, especially in developing countries. The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/(COVID-19) leads to the infection of many patients with underlying chronic liver diseases. As a relatively new disease, management of COVID-19, in the context of chronic liver disease, is mainly based on the experience of the treating physician and the available data. In this review, we summarize the available evidence about the management of liver disease patients, in the context of COVID-19 infection, which can increase the severity of viral hepatitis B. Also, its clearance in HBV patients is delayed. A sixfold increased severity of COVID-19 was reported in obese patients with metabolic associated fatty liver disease (MAFDL). In patients with autoimmune liver disease (AILD), it is not recommended to change their immunosuppressive therapy (as long as they are not infected with COVID-19), in order to avoid a flare of liver disease. However, immunosuppressant drugs should be modified, in the case of infection with COVID-19. To date, no data suggest an increased risk or severity in metabolic liver diseases, such as hemochromatosis, Wilson’s disease, or alpha-1 antitrypsin deficiency. Patients with liver cirrhosis should be carefully managed with minimum exposure to healthcare facilities. Basic investigations for follow-up can be scheduled at wider intervals; if patients need admission, this should be in COVID-19-clean areas. Patients with hepatocellular carcinomas may have a poor prognosis according to preliminary reports from China. The course of COVID-19 in liver transplant recipients on immunosuppression seems to have a benign course, based on few reports in children and adults. The hepatotoxicity of COVID-19 drugs ranges from mild liver enzyme elevation to a flare of underlying liver diseases. Therefore, the decision should be customized. Telemedicine can minimize the exposure of healthcare workers and patients to infection with COVID-19 and decrease the consumption of personal protective equipment.